eMedicine Specialties > Obstetrics and Gynecology > Gynecologic Surgery
Surgical Treatment of Vaginal Cancer: Treatment
Updated: Dec 10, 2007
Treatment
Medical Therapy
Until the discovery of radium, surgical excision was the only available treatment. In 1929, Taussig first reported radiation therapy at the Barnard Free Skin and Cancer Clinic in Boston, where he treated 18 patients with vaginal carcinoma. Only 2 of the patients survived longer than 5 years. During October of 1934, Taussig stated before the Clinical Congress of the American College of Surgeons that "primary cancer of the vagina is very rare and almost universally fatal. We acknowledge our total inability to do anything effective" to treat this disease.
Since then, radiation therapy has largely replaced surgical excision; today, radiotherapy is the treatment of choice for most cases of primary vaginal carcinoma. Still, no consensus exists regarding the proper treatment of this particular cancer, partly because of the rarity of the disease. Treatment is individualized and depends on the histologic type, stage, and location of the lesion; the presence or absence of the uterus; and whether the patient has received previous irradiation. It also depends on the medical condition of the patient and a risk-benefit analysis of all possible treatment modalities. Treatment consists of radiation therapy, surgery, or a combination of both with occasional chemotherapy.
Psychological and anatomic considerations are important in planning the treatment regimen. For example, the physician must ask the patient if she can withstand the physical and physiological alterations of an exenteration. Other issues that must be addressed are radical versus conservative approach, the patient's wishes regarding maintenance of a functional vagina, and the close proximity of the bladder and rectum to the vagina, which may limit the dose of radiation and restrict surgical margins.
Surgical Therapy
The following are treatment options and surgical procedures in several types of primary vaginal cancer.
Squamous cell carcinoma
Stage I disease involving the upper posterior vagina is treated by radical hysterectomy, partial vaginectomy, and bilateral pelvic lymphadenectomy. Lymphadenectomy is required to ensure that metastatic disease is not present. If the patient had a previous hysterectomy, then a radical upper vaginectomy with pelvic lymphadenectomy is performed after the paravesicular and pararectal spaces are developed to avoid injury to the bladder and rectum, respectively. Each ureter is also dissected out to its point of entry into the bladder. If the lesion is multifocal or if it extends to the lower third of the vagina, inguinal lymphadenectomy should also be performed, and a total vaginectomy is required. If the depth of the invasion is questioned during the operation, then a frozen section from the margins should be taken to ensure that tumor resection was adequate.
In general, tumors of the upper posterior wall are more operable because the sigmoid reflects away from the posterior vaginal wall, while the entire length of the anterior vaginal wall stays in close proximity to the bladder. A lower vaginal lesion can be treated with radical hemivulvectomy and lower vaginectomy with bilateral inguinal node dissection. Radiation therapy is commonly used as an alternative to surgery.
Stages II and III are treated with radiation therapy. In premenopausal patients, a pretreatment laparotomy is performed in order to transpose the ovaries away from the field of radiation and resect any enlarged lymph nodes. If the patient has a central recurrence with no signs of metastasis after radiotherapy, then pelvic exenteration is the only option.
Patients with stage IVa disease have the option of radiation therapy or pelvic exenteration. The latter is highly recommended if a rectovaginal or vesicovaginal fistula is present. Stage IVb is a contraindication for surgery.
Clear cell adenocarcinoma
Therapeutic considerations are very similar to those for patients with squamous cell carcinoma, although most patients are young and every effort should be made to preserve functional ovaries and vagina. Surgery is the primary treatment modality.
In stage I and early stage II disease, radical hysterectomy, pelvic lymphadenectomy, and vaginectomy with split-thickness skin graft have been successful. Alternatively, in 1987, Senekjian and colleagues reported a 5-year survival of 92% for patients with very early small lesions treated by wide local excision, laparotomy for retroperitoneal lymphadenectomy, and local irradiation to the immediate adjacent tissues.21 The best candidates are patients with tumors less than 2 cm in diameter, a predominant tubulocystic pattern, and depth of invasion less than 3 cm. If radiation is used as the sole treatment, then transposition of at least one ovary up into the paracolic gutter beyond the radiation field should be done with pelvic lymph node dissection. Local excision without radiation is not recommended since Herbst and colleagues reported that 16% of patients with stage I disease have positive pelvic nodes. Pelvic exenteration is done for central recurrences after primary irradiation.
Matthews et al presented a case report of radical abdominal trachelectomy and upper vaginectomy performed on a 22-year-old woman with clinical stage I vaginal clear cell adenocarcinoma in the left fornix.22 The woman had no evidence of recurrence with regular menstrual cycles 28 months after initial surgery. The authors concluded that this procedure could be considered to conserve fertility in young women.
Melanoma
The best treatment for vaginal melanoma remains controversial. Radical surgery has been the main treatment modality, although a more conservative approach has been advocated by some authors. In 1989 Reid et al23 and Buchanan et al in 199824 , for example, showed no significant difference in 5-year survival rates or disease-free intervals for radical versus conservative surgery. On the other hand, in 1994 Van Nostrand and colleagues demonstrated that radical surgery had a significant 2-year survival advantage over conservative surgery (48% vs 20%); they recommend a radical approach to patients with lesions smaller than 10 cm2.25
Recently, detection of nodal involvement prior to radical procedures has been suggested because positive lymph nodes indicate poor prognosis; radical surgery might be unjustified. Siu et al used laparoscopic ultrasonography to successfully detect enlarged pelvic lymph nodes.26 Rodier et al used 99mTc-sulfur colloid injected around the lesion and detected the sentinel lymph node with hot spot by lymphoscintigraphy.27 Nakagawa et al succeeded in evaluating the sentinel lymph node to decide the extent of surgery using a dye injection method28 ; 1 mL of methylene blue was injected into the subcutaneous layer at the boundary between the lesion and the vaginal mucosa, followed by incision in the ipsilateral groin to detect the stained lymph node.
Radical surgery varies depending on tumor size and location. Small lesions in the upper vagina are treated by radical hysterectomy, subtotal vaginectomy, and pelvic lymphadenectomy. Lesions in the lower vagina are managed by partial vaginectomy, total or partial vulvectomy, and bilateral inguinal lymphadenectomy. Larger and more invasive lesions (>3 mm) are treated with exenterative surgery. Note that whenever vaginal mucosa is left in situ after partial or subtotal vaginectomy, frozen sections should be obtained to exclude lateral superficial spread because the most common site of initial recurrence is the vagina.
Conservative management includes wide local excision (WLE) and simple hysterectomy combined with radiotherapy and/or chemotherapy. Radiation therapy with high-dose fractions (>400 cGy/fx) has been effective in selected patients. This type of response is consistent with the higher response rate seen with cutaneous melanoma when large individual fractions are compared to conventional fractionation. Irvin et al reported in their case series a higher locoregional control using WLE followed by high-dose fractionation teletherapy compared to more radical surgical resection.29
Verrucous carcinoma
As mentioned previously, radiation therapy is contraindicated because it tends to induce aggressive cancer types. The only treatment option is surgical resection. If the lesion is small, a wide surgical excision is performed. With larger lesions, vaginectomy or exenteration is recommended. Because this tumor rarely metastasizes, dissecting the lymph nodes is unnecessary unless they appear enlarged.
Sarcoma botryoides
Because the typical patient is prepubertal, preserve ovarian function and reproductive organs. Currently, a conservative approach is used instead of an exenterative surgery. Preoperative and/or postoperative chemotherapy and radiotherapy improve the outcome. For small easily resectable tumors, the lesion is excised. Chemotherapy VAC (vincristine, actinomycin D, and cyclophosphamide) and radiotherapy follow. If the tumor is bulky, preoperative chemotherapy or radiotherapy is administered before the lesion is excised.
Endodermal sinus tumor
This very rare tumor is treated with chemotherapy VAC to reduce the tumor size. Chemotherapy is followed by partial colpectomy, radiotherapy, or both.
Vaginal leiomyosarcoma
These tumors vary in their malignancy depending on how well they are differentiated. Well-differentiated tumors are less likely to metastasize and are managed by surgical excision. Frozen sections are taken to ensure that the tumor is well contained within the surgical margins. Poorly differentiated tumors should receive adjuvant radiotherapy.
Preoperative Details
Patient selection and preoperative evaluation
The first and most important requirement for exenterative surgery is that the patient should have no underlying medical illnesses. The patient must be fit for a prolonged operation with potential blood loss and major fluid shifts. Psychological evaluation is necessary because a stable personality and supportive social environment are required because of postoperative physical and physiologic changes. In addition to tumor resectability, patient evaluation centers on whether the patient can physiologically and psychologically withstand the surgery.
Signs of systemic spread should be absent. Evaluation starts with physical examination, which includes palpation of all peripheral lymph nodes, especially the inguinal and supraclavicular nodes. The clinical triad of unilateral leg edema, sciatic pain, and ureteral obstruction suggest involvement of the posterolateral pelvic sidewall, which is a sign of lack of resectability. Each sign by itself is not a contraindication for exploratory laparotomy, although each is associated with decreased probability of resection and decreased probability of long-term survival even if resected with clear margins. Chest radiography or CT scanning of the chest, upper abdomen, and pelvis are mandatory to rule out lung, liver, and para-aortic metastasis, respectively. Any suspicious lymph node should undergo fine-needle aspiration cytology to rule out metastasis. In a 1989 report, Manetta and colleagues dismissed the need to biopsy nonsuspicious supraclavicular lymph nodes in a random fashion.
Extension of the tumor into the pelvic sidewall is a contraindication to the procedure. Unfortunately, neither CT scanning nor MRI is sensitive and specific enough to rule out pelvic sidewall involvement. This is because radiation fibrosis and chronic inflammation cannot be differentiated from cancer with these techniques.
If resectability is questionable, then an exploratory laparotomy with parametrial biopsies should be performed to rule out pelvic wall involvement. Alternatively, laparoscopy could be performed to obtain a biopsy from the pelvic wall and any suspicious lymph nodes. In 1993, Miller and colleagues reported that nearly 30% of patients undergoing exploratory laparotomy had unresectable cancer because of peritoneal disease (44%), lymph node metastasis (40%), parametrial fixation (13%), and hepatic or bowel involvement (4.5%).30
Nutritional assessment is an important preoperative consideration because malnourished patients are at higher intraoperative and postoperative risk. Anthropometrics, serum electrolytes, total serum protein, albumin, transferrin, and immunologic function need to be evaluated. The latter is assessed by calculating the absolute lymphocyte count (reference range is >2000/mm3) and by examining delayed cutaneous hypersensitivity responses to skin test antigens.
Kidney function must be evaluated because the patient is at risk for massive fluid shifts, major blood loss, and because urinary diversion is likely to be performed. Complete urine analysis with serum creatinine provides a good evaluation. Complete blood cell count is required, and hemostatic function is evaluated through patient history of bleeding and family history of coagulopathy. Also, prothrombin time (PT) and activated partial thromboplastin time (aPTT) are required because cancer is associated with coagulation abnormalities.
Consult an ECG specialist and cardiologist. Clear the patient from cardiac risks before surgery because most patients are older than 50 years and may have underlying coronary heart disease. Also, the surgery is radical and risky with unavoidable blood and fluid losses.
Realize that age by itself is not a contraindication; the patient's health is the first prerequisite for considering pelvic exenteration.
Patient counseling
Once the patient is medically cleared for surgery, she should undergo extensive preoperative counseling. During counseling, the patient should be informed that preoperative evaluation of the tumor resectability is not as accurate as intraoperative assessment; therefore, the possibility of aborting the procedure still exists. The patient should also be informed of the radical nature of the surgery and of all possible intraoperative and postoperative complications, including intraoperative mortality. She should be informed that intraoperative and postoperative blood product administration is inevitable and that postoperative ICU care and prolonged hospitalization are common.
The patient should understand and expect an alteration in her physical appearance and physiological function, such as the presence of stomas. She should also understand the possible psychological impact such alteration will have on her.
The patient should be offered vaginal reconstruction and be given the option, if it exists, to choose the donor sites for skin grafts and musculocutaneous flaps. According to a 1983 report by Andersen and colleagues, all women who underwent reconstruction thought that preoperative counseling was inadequate.31
Most importantly, the patient should know that despite the radical nature of the surgery, cure is not guaranteed.
Preoperative preparation for pelvic exenteration
Bowel preparation, mechanical and antibiotic, begins 2 days prior to the operation to reduce the incidence of postoperative infectious complications (see Protocol for preoperative bowel preparation) . In a 1977 report, Clarke and colleagues demonstrated that preoperative oral antibiotics reduce septic complications of colon surgery from 43% in unprepared patients to 9% in prepared patients.32 Patients should be well hydrated (IV fluids) starting simultaneously with bowel preparation. Total parenteral nutrition (TPN) should be considered if patients are malnourished.
Prophylactic antibiotics (usually first- or second-generation cephalosporins) are administered IV or IM immediately before the operation and continued every 6 hours for 2 additional doses. In 1992, Classen et al found that antibiotics are most effective if administered within 2 hours of surgery.33
Because of the high risk of thromboembolic diseases in this category of patients (eg, because of old age, prolonged bed rest, prolonged surgery, and cancer), prophylaxis should consist of low-dose heparin (5000 U bid), intraoperative external pneumatic compression, or both. More aggressive prophylaxis in very high-risk patients includes low molecular weight heparin (Lovenox 40 mg SC qd), warfarin, or placement of an inferior vena cava filter. When administering these medications, the surgeon must weigh the risk of postoperative bleeding against the risk of thromboembolism.
If vaginal reconstruction is desired and a transpelvic rectus abdominis myocutaneous pedicle flap (TRAM flap) is considered, then the left epigastric artery should be evaluated in patients with prior pelvic surgery, prior transverse abdominal incision, or abdominoplasty. Preoperative evaluation of epigastric patency can be performed with preoperative arteriography or intraoperative Doppler ultrasonography.
Protocol for preoperative bowel preparation is as follows:- Preoperative day 2
- Clear-liquid diet
- Tap water or Fleet enema at night (optional)
- Preoperative day 1
- Clear-liquid diet
- 1 bottle of mineral oil or 2 L polyethylene glycol at 8 am
- Oral neomycin base, 1 g every 4 hours for 3 doses
- Oral erythromycin base, 1 g every 4 hours for 3 doses
- Tap water or Fleet enema repeated until no solid stool at night
- Operative day 0 - Fleet enema repeated until clear
Intraoperative Details
Pelvic exenteration is classified as total exenteration for apical lesions involving the bladder and rectum, anterior exenteration for anterior lesions involving the bladder, and posterior exenteration for posterior lesions involving the rectum.
Procedure
The patient is placed in the low lithotomy position with stirrups supporting the hips, thighs, and knees. This allows the surgeons to work on the abdominal and perineal areas at the same time. Intermittent pneumatic compression of the calves should be continued and deep vein thrombosis (DVT) prophylaxis given preoperatively. An epidural catheter for postoperative pain control is inserted before general anesthesia. A number 16 Foley catheter is placed in the bladder and connected to straight drainage. A nasogastric (NG) tube is inserted. The stoma sites are marked.
A midline abdominal incision is made from the symphysis pubis to a point approximately 3 cm above and to the left of the umbilicus. This allows adequate exploration of the upper abdomen (eg, liver and omentum) and good exposure for pelvic surgery. The liver, omentum, abdominal peritoneum, and para-aortic nodes should be carefully palpated and the rest of the abdomen explored. Obtain biopsies from suspicious areas and send them for frozen section.
If pelvic nodes are involved, then bilateral frozen sections of the para-aortic nodes should be taken before continuing the operation. These should be sent for frozen section. The operation should be aborted if the frozen sections are positive for malignancy, if both pelvic and para-aortic nodes are positive, if peritoneal breakthrough of the tumor has occurred, or if tumor implants are present in the abdomen or pelvis.
The round ligaments are then cut at the pelvic sidewall, and the anterior and posterior leaves of the broad ligament are opened. The prevesical, paravesical, pararectal, and presacral spaces are all developed. Any enlarged lymph node is removed and sent for frozen section. If the lateral pelvic walls and ligaments are not invaded by the tumor, the operation is continued.
The anterior division of the internal iliac arteries is ligated bilaterally just after they cross the internal iliac veins. This cuts the blood supply of the uterine, vesical, and obliterated umbilical arteries. The hypogastric artery is left untouched as it carries the blood supply to the internal pudendal and inferior hemorrhoidal arteries, which constitute the main circulation to the anal canal and lower rectum. The latter are needed to perform a low rectal anastomosis. Another artery of importance is the obturator artery, which supplies the gracilis muscle used for vaginal reconstruction (neovagina).
The cardinal ligaments are divided at the sidewall; the rectal attachment to the sacrum and the vaginal attachment to the tendinous arch are divided. At this point, the rectum and the vagina are completely mobilized, allowing free access to the pubococcygeus muscle. The site of excision of the pubococcygeus muscle depends on whether an anterior or total exenteration will be performed.
Anterior exenteration
The aim is to remove the uterus, cervix, bladder, urethra, and anterior vagina while preserving the rectum and posterior vagina. This procedure is divided into a perineal phase and an abdominal phase. Intraoperative bimanual palpation ensures that the mass is completely resected.
In the perineal phase, the urethra and anterior vagina are removed. A long curved clamp is placed beneath the pubis and directed caudad and anterior to the urethra. Another clamp is placed lateral to the pubourethral ligaments and directed out under the symphysis pubis at the 2-o'clock position and then the 10-o'clock position. This isolates the right and left pubourethral ligaments for division. The anterior vaginal wall is incised with at least 4 cm of margin under direct vision from the vaginal side. The levator ani is divided anterior to rectum, allowing removal of the specimen that includes the urethra and anterior vagina.
In the abdominal phase, the ureters are transected below the level of the common iliac arteries. The bladder is separated from the retropubic space, and the lateral vesicle attachments are sharply incised. The uterosacral ligaments are cut, and the uterus is removed with the bladder, fallopian tubes, and ovaries.
An omental J-flap is made by incising the omental attachment to the colon from the hepatic flexure medially to the midportion of the stomach. The left gastroepiploic artery becomes the blood supply of this pedicle. The flap is mobilized and brought down to the left pelvic gutter and into the pelvis where it is sewn to the posterior vaginal mucosal over the rectum and to the pelvic sidewalls. It will be used to cover the denuded area of the rectum and provide a receptacle for neovaginal construction by a split-thickness skin graft. In 1984, Hatch described use of the bulbocavernosus flap if there is not enough omentum. A continent vesicostomy is constructed, and Hemovac drains are placed in the pelvis.
Supralevator total exenteration
This procedure is similar to anterior exenteration, except that the rectum involved by the tumor is removed en bloc with the whole vagina, cervix, uterus, and bladder. It differs from the classic total exenteration by the performance of a low rectal anastomosis as opposed to a permanent colostomy. This procedure became possible with the advent of circular stapling. In order to perform this anastomosis, the anal canal and the levator ani should be free of any tumor involvement and preserved during surgery.
The sigmoid is usually divided to allow for better exposure and development of the presacral space. The superior rectal and middle rectal arteries are ligated and severed, which allows the rectum to be cut from its blood supply.
The vaginal mucosa is incised about 1-2 cm inside the hymenal ring. The bladder, vagina, and urethra are detached from the pelvic walls above the levator ani, so they are loose and attached only by the rectum.
Using a thoracoabdominal stapling device, the rectum is resected at its lower end, which leaves a 4-cm margin, and the whole specimen is removed en bloc. Before applying this device, continuous cephalad traction is applied to the rectum while holding its base above the levator ani. This provides adequate exposure of the rectum and easy access for the stapling device. Preserving enough of the lower rectum to allow the patient good continence and stool storage after the low rectal anastomosis is advisable. This step is performed by first severing the sigmoidal arteries in order to mobilize the left colon. The inferior mesenteric arteries are preserved because they will supply the sigmoid. A colonic J-pouch is formed from the sigmoid, and the low anastomosis to the stump of the lower rectum is performed using the stapling device. As with the anterior exenteration, the omentum is mobilized and used to cover the denuded pelvic area and reinforce the stapled anastomosis.
A continent vesicostomy and a neovagina are performed. Contrary to the neovagina constructed in the anterior exenteration in which the posterior vaginal wall is preserved, the omentum in this case might be insufficient for a split-thickness skin graft. For this reason, the rectus abdominis muscle or the gracilis muscles in the medial thigh are good alternatives as a source of a myocutaneous graft.
Classic total exenteration
As mentioned above, this procedure is indicated when the levator ani are involved and need to be resected with the rest of the anus. The procedure is similar to the supralevator total exenteration; however, after mobilizing the whole specimen, a perineal incision is made around the anus, leaving a generous margin from the center of the tumor. Both the anococcygeal and pubococcygeal muscles are divided along the margin.
This procedure results in a large defect in the perineum, and reconstruction is done using the bilateral gracilis or the rectus abdominis muscles as a myocutaneous flap to fill in the defect. The omentum flap is used as a protective barrier against potential intestinal adhesions, and it provides additional blood supply to the reconstructed pelvis and perineum. A permanent colostomy and continent vesicostomy are performed.
Posterior exenteration
The procedure is similar to the total exenteration, but the bladder and urethra are preserved.
Vaginal reconstruction
A neovagina can be constructed in several ways. The procedure depends on how much vaginal tissue is preserved after the exenteration as well as the size of the pelvic or perineal defect.
A split-thickness graft is usually used when an anterior or a supralevator exenteration was performed because these procedures leave a smaller defect. The mobilized omentum is used to create a pocket to receive the neovagina. A split-thickness skin graft is obtained from either the buttock (cosmetic advantage) or the anterior or medial thigh (more accessible and more comfortable postoperatively). The skin graft is sewn over a vaginal stent, preferably a Heyer-Schulte stent because it is inflatable and has its own drainage. The stent is inserted through the introitus into the omental pocket, which provides a blood supply to the graft.
Myocutaneous flaps are preferred whenever the defect is larger, such as after a total exenteration. The 2 most common flaps are the TRAM flap and the gracilis myocutaneous flap.
For a TRAM flap, the rectus abdominis on the side of the abdominal incision is used. The full thickness of the muscle, fascia, and skin are sutured from side to side with one end left open and the skin facing the inside, which forms a tubular musculocutaneous mass. The tubular neovagina is mobilized into the pelvis, and the open end sutured to the intact vaginal introitus.
For a gracilis myocutaneous flap, 2 flaps are needed. They are obtained from both medial thighs after incising the overlying skin and transecting the gracilis muscles distally. On each side, the flap is mobilized beneath a skin bridge of the vulva, which separates the vaginal introitus from the proximal pedicle. The flap should be about 5 X 10 cm to be adequate. The 2 flaps are sutured end to end into a cylindrical shape with the skin facing the inside. The neovagina is inserted into the pelvis, and the open end is sutured to the introitus. The apex is sutured to the symphysis pubis and to the anterior sacrum. Finally, the omentum is mobilized to cover the neovagina and the rest of the pelvic floor.
The disadvantage of the gracilis myocutaneous flap is the presence of incisions on both inner thighs; the TRAM flap requires no additional incisions. The TRAM has the disadvantage of a limited amount of tissue that can be mobilized from the anterior abdomen without causing much tension during closure of the abdominal incision and creating an abdominal wall distortion.
A third myocutaneous flap, the vulvobulbocavernosus pedicle, was described in 1984 by Hatch in the construction of a neovagina after exenteration.34 Originally, this pedicle was used in repairing radiation-induced rectovaginal fistulae (Martius procedure). An incision is made over each labia majora, and the bulbocavernosus muscles are mobilized on their posterior pedicles by transecting them anteriorly. Each flap is tunneled under the skin just lateral to the posterior introitus, and once inside the perineal defect, they are sutured together forming a neovagina.
Other procedures discussed in the treatment section are briefly described below.
Radical hysterectomy
The objective of a radical hysterectomy is to resect the tissue adjacent to the cervix and vaginal fornices along with removal of the uterus, cervix, and part of the vagina involved by the lesion while preserving a functional urinary apparatus and rectum.
The procedure starts with a midline incision as previously described for exenteration. Alternatively, a low transverse Maylard or Cherney incision provides adequate exposure to the pelvis but not enough to explore the entire abdomen. For this reason, a midline incision is preferable. Abdominal exploration is done as previously described.
Steady upward traction is applied to the uterus, and the retroperitoneum is entered through the round ligaments on both sides. Once the ureter is identified as it crosses the pelvic rim, the pelvic spaces are developed as before. The vesicouterine fold of the peritoneum is opened, and the bladder is dissected away from the cervix and upper vagina. If the bladder is involved, then an anterior exenteration is performed. The uterine artery is ligated at its origin from the superior vesicle or internal iliac artery and then mobilized over the ureter. The uterine veins are clipped to avoid excessive bleeding.
The anterior vesicouterine ligament, which forms the roof of the uteric tunnel, is carefully dissected. This allows mobilization of the ureters off their peritoneal attachments and away from the uterus. Care must be taken to avoid severing the blood supply to the ureters. Once this is done, the posterior vesicouterine ligament could be divided. This frees the uterus from its anterior attachments in the pelvis.
Posteriorly, the peritoneum over the Douglas pouch is incised and the rectovaginal space developed by applying smooth traction on the rectum. This allows dissection and division of the uterosacral ligaments mid way from the sacrum, which frees the uterus from its posterior attachment in the pelvis. To release the uterus from its lateral pelvic attachment, the cardinal ligaments are clamped and divided at the level of the pelvic sidewall, all the way across the paravaginal tissues down to the vagina.
If the ovaries are to be preserved, then the ovarian ligaments and fallopian tubes are transected. Otherwise, the infundibulopelvic ligaments are divided and the ovaries are freed from the pelvic attachments and removed with the uterus.
A vaginectomy is performed by continuing the dissection of the vesicovaginal and rectovaginal spaces and dividing the bladder and rectal pillars down to the pelvic floor. The vagina is entered anteriorly and transected at the desired level using a knife or scissors. The vault is closed, and the vaginal angles are sutured to the paravaginal tissues. The pelvic peritoneum is not closed, and drains are used only if doubt exists regarding the adequacy of hemostasis. In 1993, Jensen and colleagues reported that drains might increase febrile morbidity, pelvic cellulites, and postoperative ileus.35 A suprapubic catheter is placed in the bladder.
Vaginectomy
Vaginectomy for invasive vaginal carcinoma is radical as opposed to simple vaginectomy for VAIN. Vaginectomy may be partial, subtotal, or total, depending on the extent of the disease, how well-circumscribed the lesion is, and whether it is multifocal. The excision should include 2 cm of normal vagina distal to the lesion and the entire vagina proximal to the lesion. If more than a third of the upper vagina is removed, then vaginal reconstruction using a split-thickness skin graft is required in order to have normal sexual function.
Simple vaginectomy is indicated when invasion is suspected in a patient with VAIN. The approach usually is vaginal. In postmenopausal women with poorly estrogenized vaginal mucosa, estrogen cream can be used 2-4 weeks prior to the operation. Lugol solution is used to delineate the abnormal mucosa. Injecting saline solution into the submucosa elevates the lesion from the underlying tissue layer and helps in the excision. Usually, a 3- to 5-mm margin of healthy mucosa is adequate. For lesions located in the upper vagina, sutures are placed in the apex to place traction and the upper vagina is excised. The bladder and rectal pillars (lymph vascular pillars) are transected from their vaginal attachments. Blunt dissection is used to further remove the specimen. The surgeon must keep in mind the proximity of the ureters to the corners of the apex. The vagina is closed with interrupted biodegradable sutures.
Radical vaginectomy
When the uterus is in situ, radical vaginectomy can be approached vaginally or abdominally. If two thirds of the vagina needs to be removed, however, a combined approach is required to mobilize the distant vagina. In patients with previous hysterectomy, the abdominal approach or a combined approach is required because of a higher risk of injury to the ureters during resection of the cardinal ligaments and the proximal bladder pillars.
The vesicovaginal (anterior), rectovaginal (posterior), and 2 lateral paravaginal spaces are developed, and the bladder and rectal pillars are transected at their attachments to the bladder and rectum, respectively (as opposed to their vaginal attachments in simple vaginectomy). The ureters should be dissected away before resection of the vagina with the cardinal and vesicouterine ligaments. The specimen is resected in a similar manner as simple vaginectomy.
Postoperative Details
The NG tube is removed in the recovery room or at the end of the surgery. Upon admission to the recovery room, chest radiography is performed to rule out pneumothorax and to check the tip of the central line. When stabilized, the patient is transferred to the ICU.Fluid status is accurately measured by Swan-Ganz catheter because urine output may not be reliable (because of the diversion) and large loss of fluid is expected because of third spacing and oozing of serum from the large abdominal and pelvic defects. The urostomy is placed on continuous gravity drainage. Hemovac drainage should be measured and used as an indication for proper replacement of protein and electrolyte losses because drainage content is an approximation of serum content. The volume of the pelvic drainage can reach up to 1000 mL over 24 hours.
An arterial line should be available for blood products, colloid, and crystalloid administration; fluid replacement should be adequate to avoid intravascular compromise with renal hypoperfusion and failure. The hematocrit should be carefully monitored and stabilized above 30% by infusing packed RBCs or whole blood when needed. PT and aPTT are kept within the reference range with administration of fresh frozen plasma (FFP).
Routinely check the lower extremities for evidence of adequate vascular perfusion with daily checks for evidence of DVT. Continuously monitor the patient's respiratory and cardiac function for evidence of pulmonary embolus, atelectasis, pleural effusion, and cardiac ischemia. When the patient is stabilized, the Swan-Ganz catheter is J-wired and a central line is placed for TPN, usually on postoperative day 2 or 3.
Antibiotic prophylaxis is discontinued after 48 hours if no postoperative fever was reported. Otherwise, the antibiotic is changed according to the fever workup, and cultures are obtained. If the cultures are negative for infection, then the antibiotics should be changed to cover both anaerobic and gram-negative organisms.
Check stomas daily for evidence of vascular perfusion. If a stoma becomes dusky, then a scope is introduced to check the condition of the underlying bowel. Once bowel sounds are auscultated and the patient passes flatus, then oral feeding is initiated, and the TPN is withdrawn when oral intake is adequate.
Intermittent pneumatic calf compression is continued until the patient is fully ambulatory. Ambulation should begin as soon as the patient's strength is regained and pain is well controlled.
Follow-up
After the surgery, monitor the patient for complications and monitor for any sign of recurrence. No data exist regarding the frequency and effectiveness of follow-up care for recurrence. In general, patients receive a pelvic examination and Pap smear every 3-6 months for the first 5 years. Patients treated for clear cell adenocarcinoma need to be monitored for a long time because late recurrences and second primaries in DES-exposed women have been reported to occur 17-20 years after the initial treatment, particularly in the lungs and supraclavicular areas. As many as 36% of recurrences appear in extrapelvic sites.
Follow-up for postoperative complications includes evaluation of the stomas, observation of the incisions for healing, and evaluation for signs of necrosis of split-thickness skin grafts and musculocutaneous flaps. Psychologic evaluation includes questions about quality of life, body image, and sexual satisfaction. Patients should be counseled about these issues.
For excellent patient education resources, visit eMedicine's Cancer and Tumors Center, Women's Health Center, and Procedures Center. Also, see eMedicine's patient education articles Vaginal Bleeding, Colposcopy, Cervical Cancer, and Bladder Control Problems.
Complications
Exenteration
The overall mortality rate is less than 5%, but complications occur in about 50% of patients because of the nature and length of surgery, the advanced age of the patients, the large amount of blood loss, and the inability to accurately monitor fluid intake and output secondary to urinary diversion. Hemorrhage is the most significant intraoperative complication (1.5-4 L).
Postoperative complications
Hemorrhage should be dealt with promptly with percutaneous embolization because reexploration carries high mortality and morbidity rates. Intravascular fluid loss from wound oozing and third spacing is expected (see Postoperative details).
Pelvic sepsis (10%) and wound sepsis and dehiscence (12%) are minimized by bowel preparation, but the risk is still present because of the radical nature of the surgery, the length of the operation, and the age of the patient.
Pulmonary embolus occurs in 1.5% of patients despite prophylaxis. This is also due to the length of the operation and prolonged bed rest after surgery.
Lower rectal anastomosis complications
Anastomosis leak depends on the distance of the anastomosis from the anus as well as the vascularity and tension on the anastomotic site. Along with fistulae, it carries a very high mortality rate of approximately 50%.
Rectovaginal fistulae and strictures are more common in patients with previous irradiation. Using the omentum as an additional blood supply could prevent this. The inability to empty the J-pouch is the most significant drawback to this procedure.
Small bowel obstruction occurs in 4-9% of patients. The most common site is the distal ileum if an ileal anastomosis was performed, and it most frequently occurs when previous irradiation was administered. Avoiding an ileal anastomosis and generously reconstructing the pelvic floor decreases this complication. In case of an obstruction, reoperation should not be considered because of its high mortality rate (8-10%). Instead, NG decompression should be attempted and TPN feeding continued.
Fistulae (12-32%) are more common with ileoileal anastomosis and previous irradiation. With the use of a transverse colon conduit for urinary diversion, this complication now is uncommon.
With the use of a transverse colon, urinary leaks and intestinal fistulae now are rare. In case they occur, management is conservative because of the high mortality rate associated with reoperation. Percutaneous drainage is required. Ureteral strictures are uncommon with the use of stents. The long-term complication is pyelonephritis.
Other complications
TPN complications include pneumothorax (1-2%), which is diagnosed on the basis of chest radiographic findings. It usually resolves spontaneously, but a chest tube might be required.
Subclavian venous thrombosis occurs in 5-10% of patients. Flush with heparin solution (300 U/mL) for prevention. Once it occurs, remove the catheter, administer a full course of heparin, and continue nutrition through a peripheral vein.
Infection occurs in 2-5% of patients. If the patient is febrile and the source of infection is not identified after 96 hours, remove the catheter and send the catheter tip for culture. If a peripheral source was identified, then removing the catheter is unnecessary; treat the infection accordingly.
Metabolic complications include overfeeding (most common, leads to excess carbon dioxide production), hyperglycemia (treat with insulin), and metabolic acidosis (rare with addition of acetate buffer).
Complications from vaginal reconstruction include necrosis of graft and stenosis of neovagina.
More on Surgical Treatment of Vaginal Cancer |
| Overview: Surgical Treatment of Vaginal Cancer |
| Workup: Surgical Treatment of Vaginal Cancer |
 Treatment: Surgical Treatment of Vaginal Cancer |
| Follow-up: Surgical Treatment of Vaginal Cancer |
| References |
| « Previous Page | Next Page » |
References
Bricker EM. Bladder substitution after pelvic evisceration. Surg Clin North Am. 1950;30:1511-1521.
Lee YC, Holcomb K, Buhl A. Rapid progression of primary vaginal squamous cell carcinoma in a young HIV-infected woman. Gynecol Oncol. Sep 2000;78(3 Pt 1):380-2. [Medline].
Aho M, Vesterinen E, Meyer B. Natural history of vaginal intraepithelial neoplasia. Cancer. Jul 1 1991;68(1):195-7. [Medline].
Carthew P, Edwards RE, Nolan BM. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis. Apr 2000;21(4):793-7. [Medline].
Pukkala E, Weiderpass E. Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971-1995). Int J Cancer. Mar 31 1999;81(1):56-61. [Medline].
Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. 1971. Am J Obstet Gynecol. Dec 1999;181(6):1574-5. [Medline].
Herman JM, Homesley HD, Dignan MB. Is hysterectomy a risk factor for vaginal cancer?. JAMA. Aug 1 1986;256(5):601-3. [Medline].
Hellman K, Silfversward C, Nilsson B. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956-96. Int J Gynecol Cancer. May-Jun 2004;14(3):491-501. [Medline].
Ikenberg H, Runge M, Goppinger A. Human papillomavirus DNA in invasive carcinoma of the vagina. Obstet Gynecol. Sep 1990;76(3 Pt 1):432-8. [Medline].
Ostrow RS, Manias DA, Clark BA. The analysis of carcinomas of the vagina for human papillomavirus DNA. Int J Gynecol Pathol. 1988;7(4):308-14. [Medline].
Koyamatsu Y, Yokoyama M, Nakao Y. A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. Gynecol Oncol. Sep 2003;90(3):547-51. [Medline].
Forsberg JG. Estrogen, vaginal cancer, and vaginal development. Am J Obstet Gynecol. May 1 1972;113(1):83-7. [Medline].
Robboy SJ, Young RH, Welch WR. Atypical vaginal adenosis and cervical ectropion. Association with clear cell adenocarcinoma in diethylstilbestrol-exposed offspring. Cancer. Sep 1 1984;54(5):869-75. [Medline].
Eltabbakh GH, Field JM, Trask CE. Primary vaginal squamous cell carcinoma presenting as a cystic pelvic mass. Gynecol Oncol. Feb 2000;76(2):213-7. [Medline].
Manetta A, Gutrecht EL, Berman ML. Primary invasive carcinoma of the vagina. Obstet Gynecol. Oct 1990;76(4):639-42. [Medline].
Videlefsky A, Grossl N, Denniston M. Routine vaginal cuff smear testing in post-hysterectomy patients with benign uterine conditions: when is it indicated?. J Am Board Fam Pract. Jul-Aug 2000;13(4):233-8. [Medline].
Al-Kurdi M, Monaghan JM. Thirty-two years experience in management of primary tumours of the vagina. Br J Obstet Gynaecol. Nov 1981;88(11):1145-50. [Medline].
Plataniotis GA, Kouvaris JR, Sykiotis CA. Dermal metastasis from vaginal squamous cell carcinoma. Br J Dermatol. Sep 1999;141(3):579-80. [Medline].
Tavassoli FA, Norris HJ. Smooth muscle tumors of the vagina. Obstet Gynecol. Jun 1979;53(6):689-93. [Medline].
Oudouxa A, Rousseaub T, Bridjia B. Interest of F-18 fluorodeoxyglucose positron emission tomography in the evaluation of vaginal malignant melanoma. Gynecologic Oncology. 2004;95 (3):765-8. [Medline].
Senekjian EK, Frey KW, Anderson D. Local therapy in stage I clear cell adenocarcinoma of the vagina. Cancer. Sep 15 1987;60(6):1319-24. [Medline].
Matthews CM, Morris M, Burke TW. Pelvic exenteration in the elderly patient. Obstet Gynecol. May 1992;79(5 ( Pt 1)):773-7. [Medline].
Reid GC, Schmidt RW, Roberts JA. Primary melanoma of the vagina: a clinicopathologic analysis. Obstet Gynecol. Aug 1989;74(2):190-9. [Medline].
Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol. Jun 1998;178(6):1177-84. [Medline].
Van Nostrand KM, Lucci JA 3rd, Schell M. Primary vaginal melanoma: improved survival with radical pelvic surgery. Gynecol Oncol. Nov 1994;55(2):234-7. [Medline].
Siu SS, Lo KW, Chan AB. Nodal detection in malignant melanoma of the vagina using laparoscopic ultrasonography. Gynecol Oncol. Mar 2004;92(3):985-8. [Medline].
Rodier JF, Janser JC, David E. Radiopharmaceutical-guided surgery in primary malignant melanoma of the vagina. Gynecol Oncol. Nov 1999;75(2):308-9. [Medline].
Nakagawa S, Koga K, Kugu K. The evaluation of the sentinel node successfully conducted in a case of malignant melanoma of the vagina. Gynecol Oncol. Sep 2002;86(3):387-9. [Medline].
Irvin WP, Bliss SA, Rice LW. Malignant melanoma of the vagina and locoregional control: radical surgery revisited. Gynecol Oncol. Dec 1998;71(3):476-80. [Medline].
Miller B, Morris M, Rutledge F. Aborted exenterative procedures in recurrent cervical cancer. Gynecol Oncol. Jul 1993;50(1):94-9. [Medline].
Andersen BL, Hacker NF. Psychosexual adjustment following pelvic exenteration. Obstet Gynecol. Mar 1983;61(3):331-8. [Medline].
Clarke JS, Condon RE, Bartlett JG. Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. Ann Surg. Sep 1977;186(3):251-9. [Medline].
Classen DC, Evans RS, Pestotnik SL. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. Jan 30 1992;326(5):281-6. [Medline].
Hatch KD. Construction of a neovagina after exenteration using the vulvobulbocavernosus myocutaneous graft. Obstet Gynecol. Jan 1984;63(1):110-4. [Medline].
Jensen JK, Lucci JA, DiSaia PJ. To drain or not to drain: a retrospective study of closed-suction drainage following radical hysterectomy with pelvic lymphadenectomy. Gynecol Oncol. Oct 1993;51(1):46-9. [Medline].
Brunschwig A. What are the indications and results of pelvic exenteration?. JAMA. Oct 18 1965;194(3):274. [Medline].
Morley GW, Hopkins MP, Lindenauer SM. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol. Dec 1989;74(6):934-43. [Medline].
Anthopoulos AP, Manetta A, Larson JE. Pelvic exenteration: a morbidity and mortality analysis of a seven-year experience. Gynecol Oncol. Nov 1989;35(2):219-23. [Medline].
Hawighorst-Knapstein S, Schonefussrs G, Hoffmann SO. Pelvic exenteration: effects of surgery on quality of life and body image--a prospective longitudinal study. Gynecol Oncol. Sep 1997;66(3):495-500. [Medline].
Benedet JL, Murphy KJ, Fairey RN. Primary invasive carcinoma of the vagina. Obstet Gynecol. Dec 1983;62(6):715-9. [Medline].
Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. Cancer. 1948;1:177-183.
Dixit S, Singhal S, Baboo HA. Squamous cell carcinoma of the vagina: a review of 70 cases. Gynecol Oncol. Jan 1993;48(1):80-7. [Medline].
Eddy GL, Marks RD Jr, Miller MC 3rd. Primary invasive vaginal carcinoma. Am J Obstet Gynecol. Aug 1991;165(2):292-6; discussion 296-8. [Medline].
Gallup DG, Talledo OE, Shah KJ. Invasive squamous cell carcinoma of the vagina: a 14-year study. Obstet Gynecol. May 1987;69(5):782-5. [Medline].
Goodman A. Primary vaginal cancer. Surg Oncol Clin N Am. Apr 1998;7(2):347-61. [Medline].
Gupta JC, Arora MM, Jungalwala BN. Primary melanoma of the vagina. J Obstet Gynaecol Br Commonw. Oct 1964;71:801-3. [Medline].
Hatch KD, Gelder MS, Soong SJ. Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. Gynecol Oncol. Sep 1990;38(3):462-7. [Medline].
HPV (human papillomavirus). U.S. Food and Drug Administration. Available at http://www.fda.gov/womens/getthefacts/hpv.html. Accessed 12/10/07.
Isaacs JH. Verrucous carcinoma of the female genital tract. Gynecol Oncol. Sep 1976;4(3):259-69. [Medline].
Johnston GA Jr, Klotz J, Boutselis JG. Primary invasive carcinoma of the vagina. Surg Gynecol Obstet. Jan 1983;156(1):34-40. [Medline].
Kirkbride P, Fyles A, Rawlings GA. Carcinoma of the vagina--experience at the Princess Margaret Hospital (1974-1989). Gynecol Oncol. Mar 1995;56(3):435-43. [Medline].
Koutsky LA, Ault KA, Wheeler CM. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. Nov 21 2002;347(21):1645-51. [Medline].
Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. Aug 13 2003;290(6):781-9. [Medline].
Levitan Z, Gordon AN, Kaplan AL. Primary malignant melanoma of the vagina: report of four cases and review of the literature. Gynecol Oncol. Apr 1989;33(1):85-90. [Medline].
Manetta A, Pinto JL, Larson JE. Primary invasive carcinoma of the vagina. Obstet Gynecol. Jul 1988;72(1):77-81. [Medline].
Manetta A, Podczaski ES, Larson JE. Scalene lymph node biopsy in the preoperative evaluation of patients with recurrent cervical cancer. Gynecol Oncol. Jun 1989;33(3):332-4. [Medline].
Matthews KS, Numnum TM, Conner MG, Barnes M 3rd. Fertility-sparing radical abdominal trachelectomy for clear cell adenocarcinoma of the upper vagina: a case report. Gynecol Oncol. June/2007;105(3):820-2. [Medline]. [Full Text].
Melnick S, Cole P, Anderson D. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med. Feb 26 1987;316(9):514-6. [Medline].
Perticucci S. Diagnostic, prognostic, and therapeutic considerations in invasive carcinoma of the vagina. Obstet Gynecol. Dec 1972;40(6):843-50. [Medline].
Rutledge F. Cancer of the vagina. Am J Obstet Gynecol. Mar 1 1967;97(5):635-55. [Medline].
Further Reading
Keywords
cervical cancer, vulvar cancer, premalignant disease of the vagina, human papilloma virus, HPV, cervical carcinoma, herpes simplex virus, HSV, Trichomonas vaginalis, T vaginalis, human immunodeficiency virus, HIV, sexually transmitted diseases, STDs, melanoma, exenteration
